• 1
    Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000 Mar; 52: 145176.
  • 2
    Motsinger A, Haas DW, Stanic AK, Van Kaer L, Joyce S, Unutmaz D. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J Exp Med 2002; 195: 869879.
  • 3
    Princen K, Schols D. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine Growth Factor Rev 2005; 16: 659677.
  • 4
    Hellier S, Frodsham AJ, Hennig BJ, Klenerman P, Knapp S, Ramaley P, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. HEPATOLOGY 2003; 38: 14681476.
  • 5
    Goulding C, McManus R, Murphy A, MacDonald G, Barrett S, Crowe J, et al. The CCR5Δ32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 2005; 54: 11571161.
  • 6
    Eri R, Jonsson JR, Pandeya N, Purdie DM, Clouston AD, Martin N, et al. CCR5Δ32 mutation is strongly associated with primary sclerosing cholangitis. Genes Immun 2004; 5: 444450.
  • 7
    Moench C, Uhrig A, Lohse AW, Otto G. CC chemokine receptor 5Δ32 polymorphism—a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation. Liver Transpl 2004; 10: 434439.
  • 8
    Ajuebor MN, Aspinall AI, Zhou F, Le T, Yang Y, Urbanski SJ, et al. Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD1d-restricted NKT cells. J Immunol 2005; 174: 80278037.
  • 9
    Moreno C, Gustot T, Nicaise C, Quertinmont E, Nagy N, Parmentier M, et al. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. HEPATOLOGY. 2005; 42: 854862.
  • 10
    Tiegs G. T Cells, NKT cells and NK cells in an experimental model of autoimmune hepatitis. In: GershwinME, VierlingJM, MannsMP, editors. Textbook on Liver Immunology. Philadelphia: Hanley and Belfus, Inc., 2003: 171183.
  • 11
    Van Kaer L. α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 2005; 5: 3142.
  • 12
    Algeciras-Schimnich A, Vlahakis SR, Villasis-Keever A, Gomez T, Heppelmann CJ, Bou G, et al. CCR5 mediates Fas- and caspase-8 dependent apoptosis of both uninfected and HIV infected primary human CD4 T cells. AIDS 2002; 26;16: 14671478.
  • 13
    Toyabe S, Seki S, Iiai T, Takeda K, Shirai K, Watanabe H, et al. Requirement of IL-4 and liver NK1+ T cells for concanavalin A-induced hepatic injury in mice. J Immunol 1997; 159: 15371542.
  • 14
    Durante-Mangoni E, Wang R, Shaulov A, He Q, Nasser I, Afdhal N, et al. Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J Immunol 2004; 173: 21592166.
  • 15
    de Lalla C, Galli G, Aldrighetti L, Romeo R, Mariani M, Monno A, et al. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol 2004; 173: 14171425.
  • 16
    Ajuebor MN, Hogaboam CM, Le T, Proudfoot AEI, Swain MG. CCL3/MIP-1α is pro-inflammatory in murine T cell-mediated hepatitis by recruiting CCR1-expressing CD4+ T cells to the liver. Eur J Immunol 2004; 34: 29072918.
  • 17
    Wysocki CA, Jiang Q, Panoskaltsis-Mortari A, Taylor PA, McKinnon KP, Su L, et al. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood 2005; 106: 33003307.
  • 18
    Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531562.
  • 19
    Ryan CT. Trials of aplaviroc haltered in treatment-naive patients. AIDS Clin Care 2005; 17: 107108.